 LEXINGTON, Mass., April 12, 2021 PRNewswire -- Pulmatrix, Inc. NASDAQ: PULM, is re-issuing this press release solely to correct inadvertent typographical errors under the heading Updated PUR1800 Program Guidance which incorrectly noted that Pulmatrix plans to initiate a PUR1800 Phase 2 proof-of-concept efficacy study for the treatment of AECOPD in 2021. 